Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.38 |
| ▸ | NPY1R | P25929 | 7/20 | 0.38 |
| ▸ | NPY2R | P49146 | 5/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | FURIN | P09958 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123286 | 1.00 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29630297 | 0.96 | NPY4R (0.39) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29540572 | 0.94 | NPY4R (0.39) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL31673514 | 0.93 | FURIN (0.39) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29357342 | 0.92 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29358971 | 0.92 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL7242707 | 0.92 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL7098551 | 0.92 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29358945 | 0.92 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL31110537 | 0.91 | FURIN (0.42) | NPY4RNPY1RNPY2RNPY5RFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078158-A1 | COMPOSITIONS COMPRISING CXCL10-DERIVED PEPTIDES AND METHODS OF USE THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2024050567-A2 | COMPOSITIONS COMPRISING CXCL10-DERIVED PEPTIDES AND METHODS OF USE THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078158-A1 | COMPOSITIONS COMPRISING CXCL10-DERIVED PEPTIDES AND METHODS OF USE THEREOF | CXCL10, CCL2, CXCR3 | NPY4R 1209/4885NPY1R 491/4885NPY2R 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.